KNSA
XNASKiniksa Pharmaceuticals International, plc Class A Ordinary Shares
Basic Materials · Pharmaceutical Preparations
$48.71
-2.13 (-4.19%)
15-min delayed
Drag to pan · Scroll to zoom · Hover for OHLC
Snapshot
Loading metrics…
About Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Employees
366
Country
US
IPO Date
2018-05-24
COMMUNITY · $KNSA0 theses
POST YOUR TAKE →Analyst Ratings
Loading…
Financials
Loading SEC filings…
Insider Activity
Loading filings…
Related Stocks
Loading peers…
Data is 15-minute delayed, for informational purposes only. Not investment advice. Prices via Massive.com consolidated feed. Fundamentals via FinancialModelingPrep. News via Finnhub.